Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02808884Not ApplicableCompleted

Cancer DNA Screening Pilot Study (CANDACE)

Role: collaborator

NCT02612350Completed

Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease

Role: lead

NCT02715102Terminated

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

Role: lead

NCT02665299Completed

Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy

Role: lead

NCT02778412Terminated

ctDNA in Patients With Thyroid Nodules

Role: lead

All 5 trials loaded